AOD-9604: The Growth Hormone Fragment Targeting Fat Metabolism

AOD-9604 (Anti-Obesity Drug 9604) is a modified fragment of human growth hormone (hGH), specifically comprising amino acids 177-191 of the hGH molecule with a tyrosine residue added at position 177. This 16-amino-acid peptide was developed by Professor Frank Ng at Monash University in Melbourne, Australia, based on the hypothesis that the fat-metabolizing activity of growth hormone could be isolated from its growth-promoting and insulin-antagonistic effects.

The rationale behind AOD-9604 stems from a critical observation in endocrinology: full-length growth hormone (191 amino acids) promotes both lipolysis (fat breakdown) and longitudinal growth, while also causing insulin resistance and potentially stimulating tumor growth through IGF-1 elevation. These growth-promoting and diabetogenic effects make chronic GH administration problematic for weight management. AOD-9604 was designed to retain only the lipolytic domain, eliminating the 176 amino acids responsible for growth and metabolic disruption.

The development pathway began in the 1990s at Monash University, progressed through preclinical studies showing fat-reducing effects without growth-promoting activity, and eventually advanced to human clinical trials. In 2010, AOD-9604 received GRAS (Generally Recognized as Safe) status from the FDA when used as a food ingredient — an unusual regulatory path for a synthetic peptide fragment. This history distinguishes AOD-9604 from most research peptides, which lack any formal safety designation. For context on how peptide fragments relate to their parent molecules, see our comprehensive peptide guide.

AOD-9604's mechanism of action centers on stimulating lipolysis (fat breakdown) and inhibiting lipogenesis (fat formation) in adipose tissue, without activating the growth hormone receptor's growth-promoting pathways:

Lipolytic Activity: AOD-9604 stimulates beta-3 adrenergic receptor-mediated lipolysis in adipocytes (fat cells). In vitro studies using human and animal adipose tissue demonstrate that AOD-9604 increases hormone-sensitive lipase (HSL) activity — the enzyme responsible for breaking triglycerides stored in fat cells into free fatty acids and glycerol for energy utilization. This effect is concentration-dependent, with maximal lipolytic activity observed at 10-100 nM concentrations in cell culture.

Anti-Lipogenic Activity: Beyond breaking down existing fat, AOD-9604 inhibits the formation of new fat. It downregulates fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC) — the key enzymes in de novo lipogenesis. Preclinical studies show a 30-40% reduction in lipogenic enzyme activity in treated adipose tissue compared to controls, suggesting AOD-9604 creates a metabolic environment favoring net fat loss.

No Growth-Promoting Effects: Critically, AOD-9604 does not activate the JAK2-STAT5 signaling pathway responsible for GH's growth-promoting effects. It does not increase IGF-1 levels, does not stimulate longitudinal bone growth, and does not cause the insulin resistance associated with full-length GH administration. In preclinical studies, AOD-9604 treatment produced no changes in serum IGF-1, insulin, or glucose levels at doses that significantly reduced fat mass.

Cartilage-Protective Properties: An unexpected finding from AOD-9604 research is its chondroprotective activity. Studies published in Journal of Molecular Endocrinology demonstrated that AOD-9604 stimulates proteoglycan synthesis in articular cartilage and inhibits matrix metalloproteinase (MMP) activity that degrades cartilage. This has led to additional research into AOD-9604 for osteoarthritis — a therapeutic application distinct from its original fat loss purpose. For more on fat-metabolizing peptide approaches, see our weight management peptide guide.

AOD-9604 has progressed further through clinical development than many research peptides, with Phase IIb human trial data available:

Phase IIb Clinical Trial: A randomized, double-blind, placebo-controlled trial enrolled 300 obese adults (BMI 35-40) who received oral AOD-9604 at doses of 1 mg, 5 mg, 10 mg, or 20 mg daily, or placebo, for 24 weeks. The primary endpoint was change in body weight. Results showed a dose-dependent trend in weight reduction, with the highest dose group (20 mg oral daily) showing a mean weight loss of approximately 2.8 kg versus 0.8 kg in the placebo group — statistically significant but clinically modest.

Safety Data: Across the Phase IIb trial, AOD-9604 was well-tolerated. No significant adverse events were attributed to treatment. Critically, there were no changes in fasting glucose, insulin, IGF-1, or HbA1c — confirming the preclinical finding that AOD-9604 does not cause the metabolic disruptions associated with full-length GH. Liver function tests, renal function, and hematological parameters remained normal throughout the 24-week study.

Limitations of Clinical Data: While the Phase IIb trial confirmed safety and demonstrated statistical significance, the magnitude of weight loss (approximately 2 kg net difference versus placebo over 24 weeks) was considered insufficient for regulatory approval as an anti-obesity drug. For comparison, semaglutide produces 12-16% body weight reduction over similar timeframes. This modest efficacy led the developing company (Metabolic Pharmaceuticals) to discontinue the obesity development program, though the safety profile was considered favorable.

Route of Administration Factor: The Phase IIb trial used oral AOD-9604, which has substantially lower bioavailability than subcutaneous injection. Research protocols using injectable AOD-9604 suggest potentially greater efficacy at lower doses, though controlled clinical trials comparing oral and injectable routes have not been published. The oral bioavailability of peptides is generally less than 1-2%, meaning the effective systemic dose from oral administration may have been a fraction of the nominal dose.

AOD-9604 dosing varies significantly between oral and injectable routes, reflecting the bioavailability difference. All dosing information is for research reference only:

Subcutaneous Injection

Research protocols typically use 250-300 mcg subcutaneously once daily, administered in the morning on an empty stomach. Some protocols use a loading phase of 400-500 mcg daily for the first 2 weeks before reducing to 250-300 mcg for maintenance. Injection is typically in the abdominal subcutaneous fat. Morning fasted administration is preferred because insulin — elevated in the fed state — antagonizes lipolytic activity.

Oral Administration

The Phase IIb trial used oral doses of 1-20 mg daily. If pursuing oral research, doses of 10-20 mg daily on an empty stomach reflect the clinical trial protocol. Oral administration must be on a completely empty stomach (overnight fast) with water only, as food dramatically reduces the already-low oral bioavailability of peptide fragments.

Research Protocol Duration

Research protocols typically run 8-12 weeks for initial assessments. The Phase IIb trial ran 24 weeks. AOD-9604 does not appear to require cycling — no receptor desensitization has been documented at standard doses. Continuous administration throughout the research period is the standard approach.

Reconstitution

For injectable preparations, reconstitute lyophilized AOD-9604 with bacteriostatic water. A 5 mg vial reconstituted with 2 mL gives a concentration of 2,500 mcg/mL. For a 250 mcg dose, draw 10 units on a U-100 insulin syringe. Store reconstituted solution refrigerated at 2-8°C and use within 4-6 weeks. Use our peptide calculator for precise reconstitution calculations.

Placing AOD-9604 in context with other fat-metabolizing compounds helps researchers evaluate its role in body composition research:

AOD-9604 vs. HGH Fragment 176-191: These terms are sometimes used interchangeably, but there is a distinction. HGH Fragment 176-191 is the unmodified C-terminal fragment of growth hormone. AOD-9604 is this same fragment with an added tyrosine residue at position 177, which enhances stability and lipolytic potency. In research contexts, AOD-9604 is generally the preferred compound due to its greater stability and more extensive research documentation.

AOD-9604 vs. Tesamorelin: Tesamorelin stimulates endogenous GH release, producing broad GH effects including fat loss, muscle support, and IGF-1 elevation. AOD-9604 provides only the lipolytic component without GH release or IGF-1 elevation. Tesamorelin has stronger clinical evidence (FDA-approved, Phase III data showing 15-18% VAT reduction), while AOD-9604 has a narrower but potentially safer mechanism for individuals where IGF-1 elevation is undesirable. See our tesamorelin research guide for comparison.

AOD-9604 vs. Semaglutide/Tirzepatide: GLP-1 agonists produce dramatically greater weight loss (12-21% of body weight) compared to AOD-9604 (approximately 2.8 kg absolute in clinical trials). However, GLP-1 agonists achieve this partly through appetite suppression and GI slowing, with significant nausea as a common side effect. AOD-9604's mechanism is purely lipolytic without appetite effects, potentially making it useful as an adjunct in combination protocols or for subjects who do not respond to GLP-1 agonists.

AOD-9604 vs. CJC-1295/Ipamorelin: GH secretagogue stacks raise endogenous GH, producing lipolysis alongside muscle anabolism, improved sleep, and cognitive effects. AOD-9604 isolates the lipolytic component. The broader effects of GH secretagogues may be advantageous when body recomposition (simultaneous fat loss and muscle gain) is the research objective, while AOD-9604's targeted mechanism may be preferable when pure fat loss without GH-axis stimulation is desired. Browse our research peptide catalog for verified fat-loss research peptides.

AOD-9604's regulatory status is unusual among research peptides and warrants specific attention:

FDA GRAS Designation: In 2010, AOD-9604 received Generally Recognized as Safe (GRAS) status from the FDA when used as a food ingredient. This was based on safety data from the Phase IIb clinical trial and supporting preclinical studies. GRAS status means the FDA acknowledges AOD-9604's safety for oral consumption at specified doses — a rare designation for a synthetic peptide fragment. However, GRAS status does not constitute FDA approval as a drug, and AOD-9604 cannot be marketed with therapeutic claims.

Distinction from Drug Approval: GRAS status permits AOD-9604's inclusion in food products without pre-market approval, but it does not authorize sale as a drug or dietary supplement with anti-obesity claims. Companies marketing AOD-9604 with fat-loss claims are technically in violation of FDA regulations unless they pursue a formal drug approval pathway. This regulatory ambiguity has led to varying enforcement approaches.

WADA Status: The World Anti-Doping Agency (WADA) banned AOD-9604 in 2013 as a "growth hormone releasing factor" under Section S2 of the Prohibited List. This ban made headlines when AOD-9604 was linked to several sports doping investigations. For researchers in athletic or sports science contexts, this WADA classification is an important consideration.

Australian Regulatory History: As an Australian-developed compound, AOD-9604 has a unique regulatory history in Australia. The Therapeutic Goods Administration (TGA) briefly approved AOD-9604 for a specific clinical trial application but has not granted marketing approval. The TGA's assessment of the Phase IIb data concluded that while safety was demonstrated, efficacy was insufficient for regulatory approval as an anti-obesity drug in Australia.

For broader context on peptide regulation, see our peptide legality guide.

AOD-9604's safety profile is among the best-documented in the research peptide category, benefiting from formal clinical trial data and GRAS assessment:

Clinical Safety Data: The Phase IIb trial with 300 participants over 24 weeks reported no serious adverse events attributed to AOD-9604 at any dose level (1-20 mg oral daily). Common side effects were headache, nasopharyngitis, and upper respiratory tract infection — all occurring at rates similar to placebo. No injection site reactions were reported in the oral trial, though subcutaneous injection studies in smaller cohorts report mild, transient injection site erythema in approximately 5% of subjects.

Metabolic Safety: The critical safety advantage of AOD-9604 over full-length GH is confirmed by clinical data showing no changes in fasting glucose (mean change <1 mg/dL), fasting insulin, HbA1c, or IGF-1 levels. This confirms that the lipolytic fragment does not carry the insulin-antagonistic or growth-promoting effects of intact GH. For diabetic or pre-diabetic research subjects, this metabolic neutrality is particularly relevant.

Cancer Risk: Because AOD-9604 does not elevate IGF-1, the theoretical cancer risk associated with chronic GH administration (through IGF-1-mediated cell proliferation) does not apply. No preclinical carcinogenicity has been reported, and the GRAS safety assessment included review of this endpoint.

Drug Interactions: No significant drug interactions have been documented. However, concurrent use of exogenous insulin or oral hypoglycemics should be monitored, as the lipolytic activity of AOD-9604 releases free fatty acids that can transiently affect insulin sensitivity. Thyroid medications should be monitored as well, since fat metabolism is thyroid-dependent and AOD-9604's lipolytic effects may interact with thyroid-mediated metabolic regulation.

Quality Sourcing: Research-grade AOD-9604 should meet ≥98% HPLC purity, with mass spectrometry confirming the correct 16-amino-acid sequence plus the N-terminal tyrosine modification. Batch-specific COAs are essential. Visit our about page for our quality assurance standards.

AOD-9604's targeted lipolytic mechanism makes it a logical component in multi-compound research protocols:

AOD-9604 + GH Secretagogue Stack: Combining AOD-9604 with ipamorelin or CJC-1295 provides both direct lipolytic stimulation (AOD-9604) and GH-mediated body recomposition effects (muscle preservation, sleep improvement, recovery). The GH secretagogue provides the anabolic environment while AOD-9604 adds dedicated fat-metabolizing activity beyond what endogenous GH alone produces.

AOD-9604 + BPC-157 (Joint Health Protocol): Given AOD-9604's unexpected chondroprotective properties and BPC-157's tissue repair mechanisms, this combination has gained attention in joint health research. AOD-9604's proteoglycan synthesis stimulation combined with BPC-157's angiogenic and growth factor activity could address both cartilage regeneration and surrounding tissue healing in osteoarthritis models.

AOD-9604 + Lipo-C: Lipotropic compounds (methionine, inositol, choline, B12) support hepatic fat processing and methylation, complementing AOD-9604's adipocyte-level lipolysis. This combination addresses fat metabolism at both the tissue level (AOD-9604) and the hepatic processing level (Lipo-C). See our Lipo-C guide for details.

Future Research Directions: Several promising avenues remain for AOD-9604 investigation. First, injectable versus oral bioavailability comparison studies could determine whether the modest clinical trial results reflected dose-limiting oral bioavailability rather than limited efficacy. Second, combination trials with appetite-modulating compounds could test whether adding AOD-9604's lipolytic mechanism to an appetite-suppressant backbone produces additive fat loss. Third, osteoarthritis applications represent a potentially valuable second indication, given the existing chondroprotective data and the large unmet medical need. Finally, long-acting formulations using sustained-release depot technologies could enable weekly AOD-9604 dosing, improving adherence for longer-term research protocols. For related fat-loss research compounds, explore our tirzepatide and cagrilintide guides.